keyword
MENU ▼
Read by QxMD icon Read
search

Price transparency

keyword
https://www.readbyqxmd.com/read/29768435/tuna-labels-matter-in-europe-mislabelling-rates-in-different-tuna-products
#1
Carmen G Sotelo, Amaya Velasco, Ricardo I Perez-Martin, Kristina Kappel, Ute Schröder, Véronique Verrez-Bagnis, Marc Jérôme, Rogério Mendes, Helena Silva, Stefano Mariani, Andrew Griffiths
Tuna fisheries and processing represent economic activities of paramount importance around the world. Most of these products are traded for human consumption and in general are highly demanded commodities. However, not all tuna products achieve the same market price, some consumers are willing to pay a huge amount of money for certain species (i.e. Japanese market for Bluefin tuna) while other species are rather affordable (i.e. Skipjack tuna), therefore mislabelling has been observed frequently. We collected and analysed 545 tuna samples in six European countries, including fresh, frozen and canned products, and we have investigated whether or not these products were correctly labelled under European and national legislations...
2018: PloS One
https://www.readbyqxmd.com/read/29752675/estimating-drug-costs-how-do-manufacturer-net-prices-compare-with-other-common-us-price-references
#2
T Joseph Mattingly, Joseph F Levy, Julia F Slejko, Nneka C Onwudiwe, Eleanor M Perfetto
BACKGROUND: Drug costs are frequently estimated in economic analyses using wholesale acquisition cost (WAC), but what is the best approach to develop these estimates? Pharmaceutical manufacturers recently released transparency reports disclosing net price increases after accounting for rebates and other discounts. OBJECTIVE: Our objective was to determine whether manufacturer net prices (MNPs) could approximate the discounted prices observed by the U.S. Department of Veterans Affairs (VA)...
May 12, 2018: PharmacoEconomics
https://www.readbyqxmd.com/read/29743945/evidence-on-the-cost-of-breast-cancer-drugs-is-required-for-rational-decision-making
#3
Anne Margreet Sofie Berghuis, Hendrik Koffijberg, Leonardus Wendelinus Mathias Marie Terstappen, Stefan Sleijfer, Maarten Joost IJzerman
Background: For rational decision making, assessing the cost-effectiveness and budget impact of new drugs and comparing the costs of drugs already on the market is required. In addition to value frameworks, such as the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology-Magnitude of Clinical benefit Scale, this also requires a transparent overview of actual drug prices. While list prices are available, evidence on treatment cost is not. This paper aims to synthesise evidence on the reimbursement and costs of high-cost breast cancer drugs in The Netherlands (NL)...
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/29739463/trade-offs-fairness-and-funding-for-cancer-drugs-key-findings-from-a-deliberative-public-engagement-event-in-british-columbia-canada
#4
Colene Bentley, Sarah Costa, Michael M Burgess, Dean Regier, Helen McTaggart-Cowan, Stuart J Peacock
BACKGROUND: Spending on cancer drugs has risen dramatically in recent years compared to other areas of health care, due in part to higher prices associated with newly approved drugs and increased demand for these drugs. Addressing this situation requires making difficult trade-offs between cost, harms, and ability to benefit when using public resources, making it important for policy makers to have input from many people affected by the issue, including citizens. METHODS: In September 2014, a deliberative public engagement event was conducted in Vancouver, British Columbia (BC), on the topic of priority setting and costly cancer drugs...
May 8, 2018: BMC Health Services Research
https://www.readbyqxmd.com/read/29728732/affordable-laparoscopic-camera-system-alcs-designed-for-low-and-middle-income-countries-a-feasibility-study
#5
Federico Gheza, Fadekemi O Oginni, Simone Crivellaro, Mario A Masrur, Adewale O Adisa
BACKGROUND: Minimally invasive surgical techniques (MISTs) could have tremendous benefits in resource-poor environment. There is growing interest in MISTs in most low- and middle-income countries (LMIC), but its adoption has remained limited; this is largely due to high cost of the initial setup, lack of technological backup and limited access to training among others. An affordable laparoscopic setup will go a long way in improving access to MISTs. METHODS: A common zero degrees 10 mm scope is attached on the camera of a low-price smartphone...
May 4, 2018: World Journal of Surgery
https://www.readbyqxmd.com/read/29727409/how-much-will-my-child-s-operation-cost-availability-of-consumer-prices-from-us-hospitals-for-a-common-pediatric-orthopaedic-surgical-procedure
#6
Allison R Racimo, Nakul S Talathi, Nicole A Zelenski, Lawrence Wells, Apurva S Shah
BACKGROUND: Price transparency allows patients to make value-based health care decisions and is particularly important for individuals who are uninsured or enrolled in high-deductible health care plans. The availability of consumer prices for children undergoing orthopaedic surgery has not been previously investigated. We aimed to determine the availability of price estimates from hospitals in the United States for an archetypal pediatric orthopaedic surgical procedure (closed reduction and percutaneous pinning of a distal radius fracture) and identify variations in price estimates across hospitals...
May 2, 2018: Journal of Pediatric Orthopedics
https://www.readbyqxmd.com/read/29712614/the-impact-of-price-transparency-for-surgical-services
#7
Ambar Mehta, Tim Xu, Ge Bai, Kristy L Hawley, Martin A Makary
Increasing insurance deductibles have prompted some medical centers to initiate transparent pricing. However, the impact of price transparency (PT) on surgical volume, revenue, and patient satisfaction is unknown, along with the barriers to achieving PT. We identified ambulatory surgical centers in the Free Market Medical Association database that publicly list prices for surgical services online. Six of eight centers (75%) responded to our data collection inquiry. Among five centers that reported their patient volume and revenue after adopting PT, patient volume increased by a median of 50 per cent (range 10-200%) at one year...
April 1, 2018: American Surgeon
https://www.readbyqxmd.com/read/29708214/achieving-high-value-care-for-all-and-the-perverse-incentives-of-340b-price-agreements
#8
Melanie D Whittington, Jonathan D Campbell, R Brett McQueen
Section 340B of the Public Health Service Act requires drug manufacturers to enter into price agreements with the Department of Health and Human Services. These agreements result in variation in the price paid to acquire a drug by sector, which complicates the price used in cost-effectiveness analyses. We describe the transactions and sectors in a 340B agreement using a multiple sclerosis drug. Cost-effectiveness estimates were calculated for the drug using drug prices from the manufacturer and payer perspective...
April 2018: Neurology. Clinical Practice
https://www.readbyqxmd.com/read/29707985/how-can-multi-criteria-decision-analysis-support-value-assessment-of-pharmaceuticals-findings-from-a-systematic-literature-review
#9
Katarzyna Kolasa, Vladimir Zah, Marta Kowalczyk
As budget constraints become more and more visible, there is growing recognition for greater transparency and greater stakeholders' engagement in the pharmaceuticals' pric-ing&reimbursement (P&R) decision making. New frameworks of drugs' value assessments are searched for. Among them, the multi-criteria decision analysis (MCDA) receives more and more attention. In 2014, ISPOR established Task Force to provide methodological recommendations for MCDA utilization in the health care decision making. Still, there is not so much knowledge about the real life experience with MCDA's adaptation to the P&R processes...
April 29, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29705517/crossing-the-roof-of-the-world-trade-in-medicinal-plants-from-nepal-to-china
#10
Jun He, Bin Yang, Min Dong, Yunshang Wang
ETHNOPHARMACOLOGICAL RELEVANCE: Trade in medicinal and aromatic plants (MAPs) between Nepal and China has taken place for centuries along the Tibetan border. While there is anecdotal evidence that economic development in China over the past decades, coupled with regional infrastructure development and increasing market integration, has substantially changed this trade, there are no current published studies investigating this, e.g. in terms of species and market structure. This knowledge gap impedes the development of public interventions, e...
April 26, 2018: Journal of Ethnopharmacology
https://www.readbyqxmd.com/read/29675692/uptake-of-and-expenditure-on-direct-acting-antiviral-agents-for-hepatitis-c-treatment-in-australia
#11
Barbara de Graaff, Kwang Chien Yee, Philip Clarke, Andrew Palmer
BACKGROUND: Direct-acting antiviral agents (DAAs) have revolutionised treatment for the hepatitis C virus (HCV). Currently, treatment costs between 20,000 and 80,000 Australian dollars ($A) per patient. The Australian Federal Government provided $A1 billion over 5 years to subsidise these drugs. OBJECTIVE: The aim of this paper was to evaluate the uptake and financial impact of DAA prescribing in Australia. METHODS: We undertook a retrospective analysis of Medicare prescription and expenditure data for March 2016 to August 2017...
April 19, 2018: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/29657014/resistance-delaying-strategies-on-uk-sheep-farms-a-cost-benefit-analysis
#12
Jane Learmount, Mike J Glover, Mike A Taylor
UK guidelines for the sustainable control of parasites in sheep (SCOPS) were formulated with the primary aim of delaying development of anthelmintic resistance (AR) on UK sheep farms. Promoting their use requires the engagement and commitment of stakeholders. An important driver for behavioural change in sheep farmers is evidence of economic benefits. A recent evaluation of SCOPS guidance in practice demonstrated a significant reduction in anthelmintic use, suggesting economic benefits through a direct reduction in product and labour costs...
April 30, 2018: Veterinary Parasitology
https://www.readbyqxmd.com/read/29622136/american-college-of-radiology-accreditation-performance-metrics-reimbursement-and-economic-considerations-in-breast-mr-imaging
#13
REVIEW
Matthew F Covington, Catherine A Young, Catherine M Appleton
Accreditation through the American College of Radiology (ACR) Breast Magnetic Resonance Imaging Accreditation Program is necessary to qualify for reimbursement from Medicare and many private insurers and provides facilities with peer review on image acquisition and clinical quality. Adherence to ACR quality control and technical practice parameter guidelines for breast MR imaging and performance of a medical outcomes audit program will maintain high-quality imaging and facilitate accreditation. Economic factors likely to influence the practice of breast MR imaging include cost-effectiveness, competition with lower-cost breast-imaging modalities, and price transparency, all of which may lower the cost of MR imaging and allow for greater utilization...
May 2018: Magnetic Resonance Imaging Clinics of North America
https://www.readbyqxmd.com/read/29617580/promise-and-reality-of-price-transparency
#14
Ateev Mehrotra, Michael E Chernew, Anna D Sinaiko
More than housing, food, or retirement, the cost of health care is now the most common financial concern for Americans, and almost half the adults in the United States have some difficulty paying their out-of-pocket medical costs. This is not surprising, given that the mean annual out-of-pocket..
April 5, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/29605800/an-evidence-framework-for-off-patent-pharmaceutical-review-efor-for-health-technology-assessment-in-emerging-markets
#15
Diana Brixner, Zoltán Kaló, Nikos Maniadakis, Kyoo Kim, Kalman Wijaya
OBJECTIVE: This article introduces an Evidence Framework for Off-Patent Pharmaceutical Review (EFOR), which establishes value-based criteria in a template that manufacturers use to provide evidence showing how their products meet those criteria. Health authorities in emerging markets can then use the evidence presented in the EFOR to evaluate off-patent pharmaceuticals (OPPs) in a consistent, transparent, and evidence-based manner to support policy decisions, including pricing, reimbursement, formulary listing, and drug procurement...
March 29, 2018: Value in Health Regional Issues
https://www.readbyqxmd.com/read/29599024/plastic-recycling-in-the-nordics-a-value-chain-market-analysis
#16
Leonidas Milios, Lena Holm Christensen, David McKinnon, Camilla Christensen, Marie Katrine Rasch, Mikael Hallstrøm Eriksen
There is low utilisation of plastic waste in the Nordic region and only a fraction of plastic materials go back into production processes through reuse and recycling practices. This paper aims to increase knowledge concerning factors that inhibit demand for recycled plastics, and to identify critical barriers for plastic recycling across the regional plastics value chain. A literature review and targeted interviews with key actors across the plastics value chain enabled the mapping of interactions between the major actors and identified hotspots that act as barriers to the flow of plastic materials...
March 26, 2018: Waste Management
https://www.readbyqxmd.com/read/29570024/effect-of-mold-type-and-diameter-on-the-depth-of-cure-of-three-resin-based-composites
#17
M M AlShaafi, A AlQussier, M Q AlQahtani, R B Price
OBJECTIVE: To evaluate the effects of different mold materials, their diameters, and light-curing units on the mechanical properties of three resin-based composites (RBC). METHODS AND MATERIALS: A conventional nano-filled resin composite (Filtek Supreme Ultra, 3M Oral Care, St Paul, MN, USA) and two bulk-fill composites materials, Tetric Evoceram Bulk fill (Ivoclar Vivadent, Schaan, Liechtenstein) and Aura Bulk Fill (SDI, Bayswater, VIC, Australia), were tested...
March 23, 2018: Operative Dentistry
https://www.readbyqxmd.com/read/29567205/innovative-pharmaceutical-pricing-agreements-in-five-european-markets-a-survey-of-stakeholder-attitudes-and-experience
#18
William C N Dunlop, Alexandra Staufer, Pierre Levy, Guy J Edwards
BACKGROUND: Innovative pricing agreements for medicines have been used in European markets for more than 20 years, and offer an opportunity for payers and pharmaceutical companies to align on value, optimise speed to patients, and share risk. Developing successful agreements requires alignment between key stakeholders, yet there is a lack of summative data on how current innovative agreements are used in the real-world (e.g. the level of realised access to medicines, and rebates and discounts, which are often non-transparent)...
March 8, 2018: Health Policy
https://www.readbyqxmd.com/read/29556491/an-overview-of-the-reimbursement-decision-making-processes-in-bulgaria-as-a-reference-country-for-the-middle-income-european-countries
#19
Maria Kamusheva, Mariya Vassileva, Alexandra Savova, Manoela Manova, Guenka Petrova
Background: Policy makers face a lot of challenges in the process of drug reimbursement decision-making, especially in the context of entering the market of more and more innovative medicinal products (MPs). The aim of the current study is to make an overview of the reimbursement system development and to evaluate the access of innovative medicines, which have entered the EU-market in the period 2015-2017, in Bulgaria as reference example for middle-income European country. Methods: A literature and a legislative systematic review regarding the Bulgarian reimbursement system as well as a defining the number of available innovative reimbursed MPs in 2017 in Bulgaria was made...
2018: Frontiers in Public Health
https://www.readbyqxmd.com/read/29550750/combating-corruption-in-the-pharmaceutical-arena
#20
Joel Lexchin, Jillian Clare Kohler, Marc André Gagnon, James Crombie, Paul Thacker, Adrienne Shnier
Corruption in healthcare generally and specifically in the pharmaceutical arena has recently been highlighted in reports by Transparency International. This article focuses on four areas of corruption: legislative/regulatory, financial, ideological/ethical, and communications. The problems identified and the solutions considered focus on structural considerations affecting how pharmaceuticals are discovered, developed, distributed, and ultimately used in clinical settings. These include recourse to user fees in the regulatory sphere, application of intellectual property rights to medical contexts (patents and access to research data), commercial sponsorship of ghost writing and guest authors, linkage/delinkage of the funding of research and overall health objectives to/from drug pricing and sales, transparency of payments to healthcare professionals and institutions, and credible regulatory sanctions...
March 15, 2018: Indian Journal of Medical Ethics
keyword
keyword
80684
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"